Yantai Dongcheng Biochemicals Co.,Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Yantai Dongcheng Pharmaceutical Group Co., Ltd. (formerly known as Yantai Dongcheng Biochemical Co., Ltd.) was established in 1998 and listed on the Shenzhen Stock Exchange in May 2012 (stock code 002675). After more than 20 years of development, Dongcheng Pharmaceutical has become a large pharmaceutical enterprise group covering the four fields of biochemical APIs, chemical drugs, traditional Chinese patent medicines and simple preparations and nuclear medicine, integrating drug research and development, production and sales. The group holds more than 40 subsidiary companies, including Yantai Dongcheng North Pharmaceutical Co., Ltd., Yantai Dongcheng Dayang Pharmaceutical Co., Ltd., Linyi Dongcheng Dongyuan Bioengineering Co., Ltd., Zhongtai Biological Products Co., Ltd., Dongcheng International (Hong Kong) Co., Ltd., Chengdu Yunke Pharmaceutical Co., Ltd., Shanghai Xinke Pharmaceutical Co., Ltd., Shanghai Yitai Pharmaceutical Technology Co., Ltd., and Nanjing Jiangyuan Andiko Positive Electronics Research and Development Co., Ltd, The group has established research and development branches and offices in Beijing, Shanghai, and Nanjing. As a leading domestic manufacturer of biochemical raw materials, Dongcheng Pharmaceutical has won numerous international authoritative certifications for its core products, heparin sodium and chondroitin sulfate, with excellent quality. Over 90% of its products are sold to more than 40 countries and regions around the world, such as Europe, the Americas, and the Asia Pacific. It has established long-term and stable cooperative relationships with many internationally renowned pharmaceutical companies. Dongcheng Pharmaceutical continues to strengthen its pharmaceutical business, with pharmaceutical products covering treatment fields such as cardiovascular, anti-tumor, urology, and orthopedics. In recent years, the company has entered the high-tech barrier and high growth nuclear medicine industry from a high starting point, and has successively acquired multiple domestic nuclear medicine enterprises, completing the entire industrial chain layout from diagnostic nuclear drugs to therapeutic nuclear drugs, laying a leading position in the Chinese nuclear medicine field. Dongcheng Pharmaceutical has continuously increased its scientific research investment, committed to independent innovation, and introduced high-quality talents such as Mount Taishan scholars and 973 scientists. By establishing a wide network of industry university research cooperation, we aim to introduce and transform new technologies, and lead the development of enterprises through innovation. The company has successively received honorary titles such as "National Torch Plan Key High tech Enterprise", "Provincial Enterprise Technology Center", "Provincial Engineering Technology Research Center", "Provincial Engineering Laboratory", "Provincial Marine Engineering Technology Collaborative Innovation Center", "Shandong Postdoctoral Innovation Practice Base", "Shandong Provincial Technology Innovation Demonstration Enterprise", and "Top 100 of China's Pharmaceutical Industry". Guided by the corporate mission of "Based on the East, Chengnuo Health", Dongcheng Pharmaceutical will deepen resource integration, optimize industrial structure, continuously improve its innovation ability and core competitiveness. With the goal of "global heparin expert, leading enterprise in Chinese nuclear medicine", Dongcheng Pharmaceutical will continue to move towards becoming a leading pharmaceutical enterprise in the professional field and continuously creating excellent value. |
| Headquarter | Yantai |
| Establish Date | 12/31/1998 |
| Listed Code | 002675.SZ |
| Listed Date | 5/25/2012 |
| Chairman | By Shouyi. |
| CEO | Luo Zhigang. |
| Website | www.dcb-group.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
